A new drug has been labelled a turning point in the fight against Alzheimer’s after scientists identified it as slowing the progression of the disease.
A study found that the use of donanemab slowed “clinical decline” by up to 35 per cent, allowing those diagnosed to continue performing daily tasks with independence such as managing their finances, taking medication or shopping.
